NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

July 31, 2011

Conditions

Lipid Metabolism, Inborn ErrorsHypercholesterolemia, Autosomal DominantHyperlipidemiasMetabolic DiseasesHyperlipoproteinemia Type IIMetabolism, Inborn ErrorsGenetic Diseases, InbornInfant, Newborn, DiseasesMetabolic DisorderCongenital AbnormalitiesHypercholesterolemiaHyperlipoproteinemiasDyslipidemiasLipid Metabolism Disorders

Interventions

DRUG

mipomersen sodium

200 mg/ml, in 1 ml solution for subcutaneous injection.

Trial Locations (5)

45212

Cincinnati

60654

Chicago

04210

Auburn

04005

Biddeford

04074

Scarborough